|
| Status |
Public on Sep 08, 2016 |
| Title |
CFPAC-1 CPI203 10 hrs 1 |
| Sample type |
RNA |
| |
|
| Source name |
Pancreatic ductal adenocarcinoma
|
| Organism |
Homo sapiens |
| Characteristics |
cell line: CFPAC-1
treatment: CPI203
time: 10 h
|
| Treatment protocol |
Cells were exposed to 1.6 uM CPI203 or an equal volume of DMSO for 5 or 10 hours prior to harvesting for RNA.
|
| Growth protocol |
Cell lines were cultured in a 50:50 mix of Dulbecco's Modified Eagle Medium and Ham's F-12 media (Mediatech) supplemented with 10% fetal bovine serum (Life Technologies), penicillin (100 U/ml), and streptomycin (100 μg/ml) at 37°C in 5% CO2. 3X10^5 cells were plated in 6 well dishes 16 hours prior to treatment.
|
| Extracted molecule |
total RNA |
| Extraction protocol |
RNA was isolated from cells using a RNeasy micro kit (Qiagen 74004)
|
| Label |
biotin
|
| Label protocol |
Biotinylated cDNA were prepared according to the standard Illumina protocol from 0.05 ug total RNA using amplification kit NuGEN Ovation Pico SL WTA v2, Lot # 1203210-A, followed by labeling 3 ug cDNA using kit NuGEN Encore Biotin IL Module, Lot # 1109226-A.
|
| |
|
| Hybridization protocol |
0.75 ug of cDNA were hybridized for 16 hr at 48oC on Illumina HT-12 v4 Array in an Illumina Hybridization Oven (Illumina SE-901-1001). BeadChips were washed and stained in the using standard Illumina protocols.
|
| Scan protocol |
BeadChips were scanned using the Illumina iScan Scanner running Illumina iSCAN control software v 3.3.28
|
| Description |
replicate 1
|
| Data processing |
The data were analyzed with Illumina GenomeStudio ver 2011
|
| |
|
| Submission date |
Feb 20, 2014 |
| Last update date |
Sep 08, 2016 |
| Contact name |
Andrew S Liss |
| Organization name |
Massachusetts General Hospital
|
| Department |
Surgery
|
| Lab |
Liss Laboratory
|
| Street address |
55 Blossom St
|
| City |
Boston |
| State/province |
MA |
| ZIP/Postal code |
02114 |
| Country |
USA |
| |
|
| Platform ID |
GPL10558 |
| Series (1) |
| GSE55209 |
Regulation of GLI underlies a role for BET bromodomains in pancreatic cancer growth and the tumor microenvironment |
|
